Sponsors (2)
Introduced July 31, 2025 by Richard Joseph Durbin · Last progress July 31, 2025
The bill clarifies when patent-related actions affect FDA ANDA patent certifications—improving regulatory predictability and likely speeding some generic entries and lower prices—at the cost of narrowing some patent-holder remedies and risking transitional ambiguities or litigation that could delay access and raise near-term legal costs.
Patients (particularly those with chronic conditions) and health systems will likely see faster generic entry and lower drug prices because the bill's wording (e.g., treating certain claims as a 'covered patent') reduces opportunities to unreasonably extend market exclusivity.
ANDA applicants and other stakeholders gain clearer statutory rules about when patent-related actions trigger FDA patent-certification consequences, reducing legal uncertainty and helping the Department of Health and Human Services apply ANDA provisions more consistently.
Patients and health systems could face temporary delays in generic approvals or court resolutions during transition or while parties litigate ambiguities, which may keep prices higher in the near term.
Patent holders and their investors may see weakened litigation-based remedies and narrower triggers for blocking generics, potentially reducing returns on drug R&D and long-term incentives for innovation.
If statutory edits are poorly drafted or contain odd insertions, the changes could spawn litigation over interpretation and increase legal costs for both brand and generic firms, imposing compliance and litigation burdens on small businesses.
Based on analysis of 2 sections of legislative text.
Alters ANDA patent-litigation timing language by replacing 'an action is brought for infringement' with 'an action with respect to a patent or a covered patent' and adds 'covered patent' references.
Amends the Federal Food, Drug, and Cosmetic Act's drug-approval provisions to change how certain ANDA-related patent-litigation timing rules are phrased and applied. The bill replaces timing language tied to an "action brought for infringement" with timing tied to "an action with respect to a patent or a covered patent," inserts the Act's short title into specified subsections, and adds the term "covered patent" alongside existing "patent" references to narrow or clarify when litigation-triggered provisions apply. The change is largely technical but can shift when statutory triggers tied to ANDA litigation occur, which may affect generic applicants, brand companies, courts, and downstream stakeholders (patients, payers, hospitals) by altering the scope and timing of litigation-based rights and obligations. The text does not specify funding or an effective date.